Infinity Pharmaceuticals Inc. (INFI): Today's Featured Drugs Laggard

Infinity Pharmaceuticals was a leading decliner within the drugs industry, falling $0.51 (-3.1%) to $15.95 on light volume
By TheStreet Wire ,

Infinity Pharmaceuticals

(

INFI

) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.2%. By the end of trading, Infinity Pharmaceuticals fell $0.51 (-3.1%) to $15.95 on light volume. Throughout the day, 898,709 shares of Infinity Pharmaceuticals exchanged hands as compared to its average daily volume of 2,063,200 shares. The stock ranged in price between $15.74-$16.70 after having opened the day at $16.50 as compared to the previous trading day's close of $16.46. Other companies within the Drugs industry that declined today were:

Mast Therapeutics

(

MSTX

), down 40.0%,

Cardiome Pharma Corporation

(

CRME

), down 6.5%,

Hemispherx Biopharma

(

HEB

), down 6.2% and

Cormedix

(

CRMD

), down 5.6%.

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to patients for diseases with significant unmet need. Infinity Pharmaceuticals has a market cap of $776.6 million and is part of the health care sector. Shares are down 53.0% year to date as of the close of trading on Wednesday. Currently there are 6 analysts that rate Infinity Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Infinity Pharmaceuticals

as a

sell

. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, weak operating cash flow and poor profit margins.

On the positive front,

Merus Labs International

(

MSLI

), up 18.7%,

Prima Biomed

(

PBMD

), up 16.7%,

Oramed Pharmaceuticals

(

ORMP

), up 16.1% and

Celldex Therapeutics

(

CLDX

), up 14.1% , were all gainers within the drugs industry with

Pfizer

(

PFE

) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

Loading ...